• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Hydrophobic acrylic IOL combines predictable correction, rotational stability


The enVista Toric IOL was launched by Bausch + Lomb at the 2012 Congress of European Society of Cataract and Refractive Surgeons.

Milan, Italy-The enVista Toric IOL was launched by Bausch + Lomb at the 2012 Congress of European Society of Cataract and Refractive Surgeons (ESCRS) here.

As Bausch + Lomb’s first hydrophobic acrylic IOL for astigmatism correction, the lens features a unique single-piece, modified-C haptic design that delivers superior rotational stability compared with other IOLs, the company said in a prepared statement. The haptics feature a step-vaulted design to secure a predictable astigmatism correction and minimize posterior capsular opacification. The combination of aspheric, aberration-free technology with a glistening-free hydrophobic acrylic material helps the lens deliver a new standard in patient outcomes, according to the company.

“The new enVista Toric lens . . . extends the unique benefits of the enVista lens launched at ESCRS last year. The enVista lens is manufactured using a glistening-free, foldable hydrophobic acrylic IOL material developed by Advanced Vision Science, a Santen subsidiary,” said Cal Roberts, MD, executive vice president and chief medical officer, Bausch + Lomb. “The addition of this new lens to our portfolio means that Bausch + Lomb now offers surgeons a more complete range of IOLs to meet their patients’ needs.”

The enVista Toric lens has two key features that enhance its rotational stability: unique fenestrated, step-vaulted haptics and a 56° contact angle to provide added stability. The lens is easily implantable through a 2.2-mm incision.

The enVista TORIC lens received CE Mark approval in the European Union in April 2012 and is not approved for sale in the United States.

For more articles in this issue of Ophthalmology Times eReport, click here.

Related Videos
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
Elizabeth Yeu, MD, highlights from a corneal case report for a patient undergoing the triple procedure
William F. Wiley, MD, shares some key takeaways from his ASCRS presentation on binocularity and aperture optics.
© 2024 MJH Life Sciences

All rights reserved.